Idéal Investisseur
Français English
CAC 40 : Market open
8 054,16 pts
+0.58%


Last updated : 14/05/2026 - 10h55
🏠 Home   ➤    Stock news

Ipsen: Karen Witts Leaves Board, Pascal Touchon Takes Over as Interim Audit Committee Chair

Ipsen announced the resignation of Karen Witts from her role as a board member, effective after the Annual General Meeting on May 13, 2026. Having served as the Chair of the Audit Committee since 2022, she is stepping down to focus on her other professional responsibilities.


Ipsen: Karen Witts Leaves Board, Pascal Touchon Takes Over as Interim Audit Committee Chair

Audit Committee Succession Entrusted to Pascal Touchon

Karen Witts, who has been a board member at Ipsen since January 20, 2022, submitted her resignation to focus on her executive duties. Serving as the Chair of the Audit Committee from 2022 to 2026 and as a member of the Compensation Committee, she has contributed significantly to the Board's work over her four-year term.

Marc de Garidel, Chairman of the Board, thanked Karen Witts for "her dedication, meticulousness, and commitment during her tenure on the Board and for her significant contributions, particularly in her role as Chair of the Audit Committee."

Succession Process Underway

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
Before 9 AM every morning Euronext data AI-powered analysis

The Nominations Committee has initiated a succession process to replace Karen Witts. Pending its completion, Pascal Touchon, an independent board member and member of the Audit Committee, has been appointed as the interim Chair of the Audit Committee and, also on an interim basis, as a member of the Compensation Committee. This decision was made at the Board of Directors meeting held on May 13, 2026, following the Annual General Meeting.



Sector Santé · Pharmacie Industrie Pharmaceutique


Assurance vie

Context

Period
  • Period: 1T2026
Key reported figures
  • Revenue: 1074.9M€
Guidance from the release
  • Ipsen a réalisé un excellent début d'année 2026.
  • Croissance soutenue grâce aux trois aires thérapeutiques.
Risks mentioned
  • pression réglementaire anticipée sur de nouveaux médicaments
  • concurrence accrue sur Somatuline à cause des génériques
Opportunities identified
  • croissance des ventes totales du Groupe supérieure à 13,0 %
  • lancement de trois nouveaux programmes en phase avancée

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit